The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations.
Qiuyun FangXiaoyuan GongKaiqi LiuYujiao JiaYang SongGuangji ZhangYan LiQishan HaoYueshen MaShuning WeiBingcheng LiuYing WangHui WeiJianxiang WangYingchang MiPublished in: Experimental hematology & oncology (2022)
Very few reports elucidate the prognosis of patients with TP53 aberrations using both measurable residual disease (MRD) and the status of having undergone allogeneic hematopoietic stem cell transplantation (allo-SCT). In this study, aberrations of TP53 were analyzed using next-generation sequencing (NGS) and fluorescence in situ hybridization (FISH) in patients with Philadelphia chromosome-negative (Ph - ) ALL enrolled in a prospective single-arm clinical trial at our leukemia center. We analyzed the survival of the patients grouped according to the MRD level at the third month and whether or not received allo-SCT. We found that allo-SCT could improve the OS in patients with TP53 aberrations; Patients having negative MRD at the third month still showed worse 3-year OS and 3-year DFS without undergoing allo-SCT, which is different from previous studies, moreover, the prognostic significance of TP53 deletions was as important as TP53 mutations, the importance of screening both TP53 deletions and mutations in adult Ph - ALL at diagnosis should be emphasized.
Keyphrases
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- copy number
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute myeloid leukemia
- prognostic factors
- randomized controlled trial
- gene expression
- bone marrow
- phase ii
- dna methylation
- study protocol
- patient reported
- single molecule
- quantum dots
- double blind